Learn More-External Link
Trending at Lumira Ventures
Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
PRINCETON, N.J., Dec. 11 /PRNewswire-FirstCall/ — Pharmasset, Inc. announces that interim results of physician-sponsored studies of clevudine for the treatment of chronic hepatitis B virus (HBV) and both preclinical and clinical results of R7128 for the treatment of chronic hepatitis …
Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales
PRINCETON, N.J., Nov. 26 /PRNewswire-FirstCall/ — Pharmasset, Inc. appointed Patrick T. Higgins as Executive Vice President, Marketing & Sales, responsible for coordinating the global product launch and marketing activities for Pharmasset’s drug candidates. Mr. Higgins, who has served as a …
Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
PRINCETON, N.J., Nov. 2 /PRNewswire-FirstCall/ — Pharmasset, Inc. announces the results of a 14-day Phase 1 multiple ascending dose monotherapy study of R7128 for the treatment of chronic hepatitis C infection. In this study, being presented as a “late-breaker” abstract …
Pharmasset says R7128 has received fast track designation from the FDA…
R7128 is a prodrug of PSI-6130, an oral cytidine nucleoside analog polymerase inhibitor of HCV that is being developed through Pharmasset’s collaboration with Roche. As noted on 3-Oct, Pharmasset has commenced dosing in a 28-day Phase 1 clinical trial to …
Pharmasset’s Hepatitis C Drug Has A Promising Future
Learn More-External Link
Pharmasset Accesses up to $30 Million of Working Capital
Learn More-External Link
Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
Learn More-External Link
Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Learn More-External Link
Pharmasset and Roche to Present R7128 Data at the 14th International Symposium..
Learn More-External Link
Pharmasset and Roche Initiate Studies to Advance R7128 for HCV
Learn More-External Link
Pharmasset Completes Enrollment of Phase 1 Study of R7128 for HCV
Learn More-External Link
Pharmasset Prices Initial Public Offering
PRINCETON, N.J., April 26, 2007 /PRNewswire-FirstCall via COMTEX News Network/ — Pharmasset, Inc. (Nasdaq: VRUS) announced today that it has priced its initial public offering of 5,000,000 shares of common stock at $9.00 per share. All of the common stock …